Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

The WHO has orchestrated two mass vaccination campaigns during pauses of fighting in the ongoing war between Israel and Hamas.

The patch-delivered vaccine trial received $28.5m in funding from US authorities as a potential pandemic preparation.

Qure's AMT-130 shows 80% Huntington's progress reduction, eyeing FDA approval. Click here to read why I rate QURE stock a Buy ...

Apimeds Pharmaceuticals US (APUS) is planning to raise $20 million in an initial public offering on the week of February 24th, IPO Scoop reports. The company will be issuing 4,500,000 shares at ...

A groundbreaking study led by researchers at Insilico Medicine has revealed the potential of TNIK inhibition as an innovative ...

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for the treatment of relapsed/refractory light ...

Data reinforce dose-dependent mechanism with IMNN-001 100mg/m2 dose associated with 20% increase in IL-12 levels compared to 79mg/m2 dose Results from OVATION 2 Study continue to validate TheraPlas® ...

Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...

Milestone's NDA for CARDAMYST is currently under review at the FDA with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025. The Company continues to advance commercial preparations ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...